Quinina

Quick links to important sections

Quinina

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quinina

Property Description
Active ingredient Quinine (often as Quinine sulfate)
Form Capsules (oral), Solution (injection)
Pharmacological class Antimalarial quinoline
Common use Treatment of malaria
Origin Natural (Cinchona tree alkaloid)

What is Quinina and What Type of Medicine is it?

Quinina refers to the medicine containing the active ingredient Quinine, classified primarily as an antimalarial quinoline agent. This single-ingredient product is fundamentally used to interrupt the life cycle of the Plasmodium parasites that cause malaria.

Quinine is a powerful alkaloid with established anti-parasitic properties, clinically recognized for its essential role in treating parasitic infections where drug resistance is a concern. Its pharmacological classification as an Antimalarial quinoline places it within a category of substances specifically designed to target and eliminate the multiplying parasitic forms that circulate in the bloodstream. The general therapeutic purpose of Quinina is to act as a blood schizonticide, providing a necessary intervention for the treatment of parasitic infection and is recognized for its clinical importance.


The Origin and Composition of Quinina

Quinine is a substance of natural origin, historically derived from the bark of the Cinchona tree, a differentiating factor as one of the few core antimalarials originating as a traditional remedy. The medicine is commonly formulated using the salt, Quinine sulfate, to ensure appropriate pharmaceutical stability and absorption in the body.

As a therapeutic entity, Quinina is typically available in the form of oral Rx-only capsules for ease of use, though a sterile solution for injection is also manufactured for situations requiring intravenous administration in severe cases. The active component, Quinine sulfate, works by targeting the parasites within the red blood cells, interfering with a crucial internal detoxification process required for the parasite's survival and proliferation. Pharmacological studies confirm this interference with the parasitic lifecycle affirming its long-standing therapeutic status.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Quinina?

Possible Side Effects and Safety Information

The safety profile of Quinina is officially documented through regulatory classifications which group adverse effects by frequency and the body system affected. The most frequently observed non-serious effects are known collectively as Cinchonism, a cluster that often includes tinnitus, headache, dizziness, visual disturbances, and gastrointestinal effects such as nausea and vomiting. These symptoms are generally classified as Common or Very Common in regulatory documents.

Documented Serious Adverse Reactions

Official labeling emphasizes the potential for serious, yet rare, adverse reactions affecting critical organ systems:

  • Cardiac Disorders: A primary safety concern is the risk of QT interval prolongation which can lead to severe ventricular arrhythmias, including Torsade de Pointes. This risk is acknowledged in the official safety constraints.
  • Blood and Lymphatic Disorders: Serious hematological events are documented, including potentially life-threatening thrombocytopenia (low platelet count), hemolytic anemia, and Blackwater Fever.
  • Metabolic and Immune: Severe hypoglycemia and serious hypersensitivity reactions (e.g., anaphylaxis) are also listed as recognized adverse events.

Population-Specific Safety Constraints

Regulatory documents include specific limitations for certain populations. The medicine is contraindicated in individuals with a history of quinine-induced severe hypersensitivity, pre-existing prolonged QT interval, or active optic neuritis. Furthermore, close monitoring is required for patients with G6PD deficiency (risk of hemolysis) and those with severe renal impairment. The safety profile notes that Cinchonism symptoms are generally dose-related and often reversible upon cessation of use.

Overdose and Emergency Response

Overdose and When to Seek Help

Quinine overdose is a serious medical event due to the risk of life-threatening and potentially fatal complications documented in official regulatory labeling. Immediate medical attention is required for any suspected overdose.

Documented Overdose Manifestations

Overdose typically presents as a severe progression of Cinchonism. Ocular toxicity is a key concern, with symptoms ranging from blurred vision and disturbed color perception to permanent or irreversible visual loss and total blindness. Other documented manifestations include severe headache, profuse vomiting, tinnitus, and neurological effects such as confusion, seizures, and coma.

Severe Outcomes and Emergency Action

Regulators emphasize the primary life-threat: cardiovascular toxicity. This includes severe hypotension and the risk of ventricular arrhythmias, such as Torsades de pointes. Other severe outcomes documented are respiratory arrest, significant hypoglycemia, and thrombocytopenia which can lead to fatal hemorrhage.

Due to these risks, all patients with suspected intoxication must undergo continuous hospital monitoring, including mandatory ECG monitoring of the QT interval and frequent checks for hypoglycemia. Treatment is strictly supportive and symptomatic, and may involve the administration of multiple-dose activated charcoal. Clearance of the medicine is officially noted to be decreased in the elderly and in those with severe chronic renal failure, potentially increasing toxicity risk in these populations.

Therapeutic Uses of Quinina

What Quinina Treats: Main Uses and Benefits

Quinina is applied within the therapeutic domain of antimalarial management, primarily for conditions presenting with acute episodes of malaria. This use is relevant when the infection is caused by drug-resistant strains of the Plasmodium falciparum parasite. The medicine is relevant for parasite clearance, which supports the management of conditions marked by increased physiological stress.

The medicine is applied in therapeutic domains involving certain distressing symptoms related to parasitic illnesses. Quinina is also relevant in conditions involving episodic or fluctuating manifestations related to Babesiosis, a protozoal illness.

Symptom Relief and Clinical Context

The medicine is commonly used to help manage symptom clusters that may become intense or disruptive that accompany the active infection. This involves helping to manage symptoms related to heightened physiological activity, such as cyclical high fever, recurrent chills, and drenching sweats, alongside systemic symptoms like headache and fatigue. Quinina contributes to easing the overall symptom load and supports general well-being during symptomatic periods.

“The medicine is used when symptoms create noticeable physiological strain and interfere with daily comfort.”

Quick Fact: Supportive Role in Acute Febrile States

Quick Fact: Supportive Role in Acute Febrile States. Quinina is applied in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Quinina — official regulatory information

Eligibility scope

Classification Populations and Conditions
Populations for whom use is contraindicated Patients with a prolongation of the QT interval, Myasthenia gravis, Optic neuritis, or a known hypersensitivity to quinine, mefloquine, or quinidine. Contraindication also applies if a patient has a history of serious immunoallergic reactions (e.g., thrombocytopenia, blackwater fever, or hemolytic uremic syndrome) following quinine exposure.
Use is explicitly NOT recommended The drug is not approved and should not be used for the treatment or prevention of nocturnal leg cramps. Use should be avoided in patients with clinical conditions that prolong the QT interval (e.g., uncorrected hypokalemia or clinically relevant bradycardia).
Special Considerations/Restrictions Dosage adjustment (reduction) is required for patients with severe chronic renal impairment. Use in patients with severe (Child-Pugh C) hepatic impairment is generally not advised. Patients with atrial fibrillation or flutter require caution due to the risk of a paradoxical increase in ventricular rate. Use in patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency may result in hemolytic anemia, requiring cautious assessment.
Age-related Eligibility Generally considered acceptable for adults and pediatric use at doses recommended for the approved malaria indication. Older adults may be at higher risk for adverse effects and should be monitored closely.
Pregnancy/Lactation Quinine is often recommended for malaria treatment in all trimesters of pregnancy; however, use for the unapproved indication of leg cramps is prohibited during pregnancy. The drug is generally considered compatible with breastfeeding.

Connection to the overall eligibility profile

Quinine is reserved for its official use in treating uncomplicated P. falciparum malaria, with regulatory bodies strictly prohibiting its use for nocturnal leg cramps due to the risk of serious and potentially life-threatening hematologic and cardiac adverse events. Eligibility is defined by a narrow profile, excluding patients with specific pre-existing conditions, most notably those that affect cardiac conduction (QT prolongation), neuromuscular function, or hematological health. Use requires careful clinical consideration, including dose reduction for severe kidney impairment, emphasizing that eligibility is highly dependent on both the patient's physiological state and the approved therapeutic context.

What should I know about interactions with other medicines?

Quinina Interactions with other Medicines and Products

Quinine's official interaction profile, documented by regulatory authorities, centers on specific pharmacokinetic and pharmacodynamic effects with other medicinal products.


Formal Contraindicated Combinations

The most stringent restriction is the formal contraindication against co-administering Quinine with any medicine known to prolong the QT interval (e.g., Amiodarone, Moxifloxacin) due to the risk of serious cardiac arrhythmias. Additionally, the label cautions against concomitant use with strong CYP3A4 inhibitors (like Macrolide Antibiotics) and strong CYP3A4 inducers (like Rifampin).


Documented Metabolic and Other Interactions

Quinine is noted to be an inhibitor of CYP3A4 and CYP2D6 enzymes, meaning it can increase the systemic exposure of other drugs metabolized by these pathways. Conversely, its own clearance is affected by co-administered medicines, with CYP3A4 inhibitors raising Quinine levels and inducers lowering them. Pharmacodynamic interactions include the potentiation of neuromuscular blocking agents and the enhanced effect of oral anticoagulants.


Administration and Population Cautions

Specific products like aluminum and magnesium-containing antacids should not be administered concomitantly as they interfere with Quinine absorption. Regulatory information also notes that Quinine clearance is significantly decreased in the elderly and in patients with severe hepatic impairment, necessitating awareness of potentially heightened interaction risk in these populations.

Mechanism of Action

Quinina is a cinchona alkaloid that exerts its primary action by concentrating within the acidic food vacuole of the intraerythrocytic Plasmodium parasite. Within this organelle, the parasite degrades host hemoglobin as a nutrient source, releasing the cytotoxic byproduct heme (ferriprotoporphyrin IX). Normally, the parasite detoxifies heme by polymerizing it into an inert crystalline substance called hemozoin.

Quinina interferes with this essential detoxification pathway. It is proposed to bind directly to free heme, forming a drug-heme complex. This interaction prevents the biocrystallization of heme into hemozoin, leading to a critical build-up of unpolymerized, toxic heme within the parasite's food vacuole. The accumulated heme induces oxidative damage to the parasite's membranes and organelles, which results in irreversible disruption of cellular function. The alkaloid also affects other cellular processes, including potential inhibition of nucleic acid synthesis and protein synthesis within the parasite.

Dosage and Administration Information

Administration and Dosing Instructions

The correct use of Quinina (quinine sulfate) is defined by established guidelines, which dictate the dosage, frequency, route, and duration of the treatment course.

Route of Administration:

  • Quinina is taken by mouth (oral) in the form of capsules.

Dosing and Schedule:

Patient Group Dosing Schedule (Quinine Sulfate 324 mg Capsules) Course Duration
Adults (age 16 and older) 648 mg (two capsules) every 8 hours 7 days
Severe Chronic Renal Impairment Loading dose of 648 mg followed 12 hours later by a maintenance dose of 324 mg every 12 hours 7 days

Procedural Guidelines

  • Administration with Food: Quinina should be taken with food to minimize stomach upset.
  • Capsule Handling: The capsules must be swallowed whole and should not be opened, chewed, or crushed.
  • Missed Dose: If you miss a dose, take it as soon as you remember. However, if more than 4 hours have passed since the scheduled time, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a forgotten one.
  • Treatment Course: It is mandatory to finish the full 7-day course as prescribed, even if symptoms improve, to ensure complete adherence to the prescribed protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Quinina

This overview summarizes the types of research and general findings related to Quinina (Quinine) in official and peer-reviewed scientific literature. The evidence is derived from studies focused on specific parasitic infections and the patterns of response observed in different patient groups.


Evidence for Quinina in Uncomplicated P. falciparum Malaria

Research for Quinina has consisted primarily of Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate its use for malaria, including in settings where parasite strains may show resistance to other agents. Studies observed specific outcomes, including measurements of parasite clearance and the time required for fever to subside (Fever Clearance Time).

Findings generally describe patterns related to the short-term changes in the parasite and measurements related to symptom evolution. When observed alongside newer combination therapies, some trials reported differences in parasite clearance times. The follow-up durations were limited to the immediate post-treatment period (typically 28 to 63 days), meaning longer-term outcomes are not fully established.


Research on Quinina for Severe P. falciparum Malaria

Research for Quinina in severe malaria relies on large multicentre trials and subsequent systematic reviews that historically contributed to its evaluation in severe cases. Research focused on critical outcomes reflecting physiological strain and acute change, such as the mortality rate and the time to regain consciousness.

Studies comparing newer antimalarial agents to Quinina described different measurements of mortality rates in severe malaria. The data show patterns related to its use when alternative, preferred treatments are unavailable or unsuitable in certain settings.


Evidence in Special Patient Populations

  • Children: Studies have monitored its use in children with both uncomplicated and complicated malaria. The research describes patterns observed in children with uncomplicated malaria.
  • Pregnant Women: Systematic reviews and trials have been conducted to evaluate Quinina in pregnant women during the second and third trimesters. Research indicates that Quinina was evaluated in this group, and the findings regarding specific outcomes were documented.
  • Elderly Patients: Data for this group remain insufficient. Few studies have included patients over 65 years old, meaning the specific patterns observed in the elderly are not fully established.

Evidence Gaps and Areas of Uncertainty

The evidence landscape contains recognized limitations:

  • Comparative evidence is lacking for Quinina against all modern drug combinations in certain regions.
  • For Babesiosis, the evidence is largely based on small sample sizes and case reports, meaning the certainty remains low compared to the high-level evidence available for malaria.
  • Research exploring the safe and effective use of Quinina in the elderly population has not been sufficiently conducted.

Key Studies & References

  1. Quinine Sulfate Oral Capsule Information (MedlinePlus)
  2. Quinine General Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Quinina (FAQ)


Q: How quickly should I expect Quinina to start working for fever?

Clinical studies often report on the time it took for the fever to subside (Fever Clearance Time) or for the parasite to be cleared from the blood. However, a specific time frame for when an individual should expect their fever to break is not typically included in the official product information.


Q: How long does Quinina stay in your system after the last dose?

According to pharmacokinetic data, the average elimination half-life of Quinina in healthy adults is reported to be between 9.7 and 12.5 hours. This means that half of the drug is naturally removed from the body in that time period. Traces of the drug may remain detectable for a period longer than this.


Q: Does Quinina interact negatively with common pain relievers like ibuprofen?

Regulatory documents indicate that Quinina is an inhibitor of the CYP2D6 enzyme, a system used by the body to process many other medicines. This means Quinina has the potential to increase the systemic concentration of other medicines that are processed through this pathway. It is important to inform a healthcare provider about all medicines being taken.


Q: What foods or supplements should I watch out for that might interact with Quinina?

Official safety constraints explicitly advise against taking aluminum and magnesium-containing antacids simultaneously with Quinina, as they can interfere with the drug’s absorption. The capsules are generally recommended to be taken with food to help reduce stomach upset.


Q: What is the connection between Quinina and tonic water?

The active ingredient in Quinina, quinine, is also the flavoring agent used in tonic water. Regulatory safety constraints caution against prescribing the medicine to individuals who have previously experienced serious adverse reactions to quinine found in tonic water or other beverages.


Q: Does Quinina make you more sensitive to sunlight?

Yes, official documentation lists photosensitivity reactions among the potential adverse events of Quinina. This indicates that the medication may cause skin sensitivity to sunlight, which is medically known as a photosensitivity reaction.


Q: Does the absorption of Quinina change if taken with food?

Clinical studies show that taking Quinina capsules with a high-fat meal can prolong the time it takes for the drug to reach its maximum concentration in the blood. However, the overall amount of the drug absorbed into the body remains largely similar whether it is taken with food or while fasting.


Q: What scientific evidence supports the use of Quinina for nocturnal leg cramps?

Regulatory authorities have prohibited the use of Quinina for nocturnal leg cramps. This regulatory action was taken due to concerns that the risk of serious side effects, particularly those affecting the heart and blood cells, outweighs the potential benefit for treating this unapproved condition.


Q: Why is Quinina sometimes difficult to find or restricted in certain countries?

Quinina is highly restricted primarily because it carries a risk of serious adverse events, including QT interval prolongation which can cause dangerous heart arrhythmias. These significant safety concerns lead to formal contraindications and strict warnings that limit the eligible patient population.


Q: Can Quinina interfere with birth control pills?

Official interaction lists note that Quinina inhibits the CYP3A4 enzyme in the liver. Since many hormonal contraceptives rely on this specific enzyme for processing, Quinina has the potential to alter the levels of oral contraceptives in the body. Any potential interference would need to be assessed by a healthcare provider.


Q: Is it okay to drive or operate heavy machinery while on Quinina?

Regulatory warnings state that Quinina may cause side effects such as visual disturbances and vertigo (dizziness or spinning sensation). Official guidance advises that driving or operating machinery may be unsafe if an individual experiences these side effects.


Q: Does Quinina affect sleep patterns or cause insomnia?

Official adverse event reports include central nervous system (CNS) disturbances such as restlessness and nightmares. These types of effects may potentially interfere with regular sleep patterns.


Q: Is the taste of Quinina very bitter, and is there a way to mask it?

Official labeling dictates that the Quinina medicine must be provided in a capsule form. The oral capsule form must be swallowed whole, and it should not be opened, chewed, or crushed. This method helps prevent direct exposure to the taste and maintains the drug’s intended delivery.


Q: Are there any known psychiatric side effects associated with Quinina?

Yes, regulatory documents list neuropsychiatric effects among the possible side effects. These can include confusion, altered mental status, and disorientation. Rare, serious psychiatric events have also been noted in regulatory warnings.


Q: Why is Quinina considered a last-resort treatment in some places?

Quinina is a long-established treatment for uncomplicated malaria. It is often reserved for use in specific settings, such as when preferred newer antimalarial agents are unavailable, or where the parasite has developed resistance to other standard medications.


Q: Are there different forms of Quinina (e.g., tablet vs. capsule) and do they work differently?

Quinina is available as an oral capsule and also as a sterile solution for injection. While the oral forms are generally considered similar in terms of drug absorption, the injection is specifically reserved for severe malaria cases or when the patient is unable to take medicine by mouth.


Q: What are the signs that Quinina might be affecting my kidneys or liver?

Official warnings note that adverse events related to the liver can include granulomatous hepatitis, and for the kidneys, renal failure or impairment. Regulatory documents indicate that patients with severe chronic renal impairment require careful assessment and monitoring.


Q: Can people with a history of heart problems still take Quinina?

Quinina is contraindicated (strongly prohibited) for individuals with pre-existing conditions that prolong the QT interval or those with a history of serious heart rhythm abnormalities. Caution is also specifically advised for patients with certain other heart conditions, such as atrial fibrillation.


Q: Is Quinina known by any other trade names internationally?

While the active ingredient is Quinine sulfate, the proprietary (brand) name Qualaquin has been used in some regions for the capsule form of the medicine. The drug is often referred to simply by its generic active ingredient name internationally.

How should Quinina be stored and disposed of?

The official storage and disposal requirements for Quinine sulfate capsules are defined by regulatory labeling to maintain product stability and safety.

Storage Conditions

Quinine sulfate must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication requires protection from light and excessive moisture and must be kept in a tightly closed container. As a mandated safety requirement, the medicine must be stored out of the reach of children.

Disposal

Expired or unused quinine sulfate should be disposed of properly according to local regulations, typically via an authorized drug take-back program. To prevent environmental contamination, do not dispose of the capsules by flushing them down a toilet or pouring them into a sink unless specifically instructed by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quinina found in:

A-Z Index: